Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.
Viola F, Chi GC, Holekamp NM, Giocanti-Aurégan A, García-Layana A, Peto T, Kertes PJ, Mirt M, Kotecha A, Lambert J, Lewis HB, Gentile B. Viola F, et al. Among authors: giocanti auregan a. Ophthalmic Res. 2024;67(1):516-527. doi: 10.1159/000540390. Epub 2024 Aug 29. Ophthalmic Res. 2024. PMID: 39208778 Free article.
Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Holekamp N, Gentile B, Giocanti-Aurégan A, García-Layana A, Peto T, Viola F, Kertes PJ, Mirt M, Kotecha A, Lambert J, Lewis HB, Chi GC. Holekamp N, et al. Among authors: giocanti auregan a. Ophthalmic Res. 2024;67(1):311-321. doi: 10.1159/000538975. Epub 2024 Apr 29. Ophthalmic Res. 2024. PMID: 38679018 Free article.
Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.
Dupas B, Castro-Farias D, Girmens JF, Eginay A, Couturier A, Villeroy F, Delyfer MN, Creuzot-Garcher C, Giocanti-Auregan A, Béral L, Arndt C, Mesnard C, Vicaut E, Chaumet-Riffaud P, Durand-Zaleski I, Paques M. Dupas B, et al. Among authors: giocanti auregan a. Trials. 2024 Apr 22;25(1):273. doi: 10.1186/s13063-024-07994-1. Trials. 2024. PMID: 38649937 Free PMC article.
[One retinopathy can mask another].
Timoumi R, Giocanti-Aurégan A, Fajnkuchen F, Torres-Villaros H. Timoumi R, et al. Among authors: giocanti auregan a. J Fr Ophtalmol. 2024 Mar;47(3):104046. doi: 10.1016/j.jfo.2023.104046. Epub 2024 Jan 11. J Fr Ophtalmol. 2024. PMID: 38216406 French. No abstract available.
Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study.
Donati S, Yang CH, Xu X, Mura M, Giocanti-Aurégan A, Hoerauf H, Allmeier H, Machewitz T, Johnson KT, Santoro E; AURIGA study investigators. Donati S, et al. Among authors: giocanti auregan a. Ophthalmol Ther. 2024 Jan;13(1):161-178. doi: 10.1007/s40123-023-00829-3. Epub 2023 Nov 4. Ophthalmol Ther. 2024. PMID: 37924483 Free PMC article.
[Baló's concentric sclerosis: Case report].
Derrien M, Louis-Philippe S, Janicot L, Fajnkuchen F, Giocanti-Aurégan A. Derrien M, et al. Among authors: giocanti auregan a. J Fr Ophtalmol. 2023 Sep;46(7):e227-e229. doi: 10.1016/j.jfo.2023.03.006. Epub 2023 Jul 3. J Fr Ophtalmol. 2023. PMID: 37407402 French. No abstract available.
100 results